太极集团：子公司司美格鲁肽注射液临床试验获批

Core Viewpoint - Taiji Group's subsidiary, Chongqing Fuling Pharmaceutical Factory, has received approval from the National Medical Products Administration for clinical trials of Semaglutide injection for type 2 diabetes treatment [1] Group 1: Clinical Trial Approval - The approved clinical trial is aimed at adult patients with type 2 diabetes for blood sugar control [1] - The indication is for adults whose blood sugar remains uncontrolled despite treatment with Metformin and/or Sulfonylureas [1] - The trial also targets reducing the risk of major cardiovascular adverse events in adults with type 2 diabetes and cardiovascular diseases [1]